Market research
0IF.F LogicBio Therapeutics, Inc
F EUR Not available
Latest close
Latest stored close unavailable
Test a moving-average rule with historical data.
Market facts
- Market cap
- 66M
- P/E ratio
- Not available
- Analyst target
- 18.8
- Dividend yield
- 0.0%
- Beta
- 4.62
Profile
Instrument facts
- Exchange
- F
- Currency
- EUR
- Sector
- Not available
- Industry
- Not available
- ISIN
- Not available
- Market cap
- 66M
- P/E ratio
- Not available
- Analyst target
- 18.8
- Dividend yield
- 0.0%
- Beta
- 4.62
About
About LogicBio Therapeutics, Inc
LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. The company has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop LB-301, an investigational therapy for the treatment of Crigler-Najjar syndrome. The company also has a research collaboration, license, and option agreement with CANbridge Care Pharma Hong Kong Limited; and collaboration agreement with Daiichi Sankyo Company. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts. As of November 15, 2022, LogicBio Therapeutics, Inc. operates as a subsidiary of Alexion Pharmaceuticals, Inc..
Research context
LogicBio Therapeutics, Inc appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the 0IF.F discussion.
5 years, 6 months ago
LogicBio Therapeutics, Inc is currently in a long term downtrend where the price is trading 37.4% below its 200 day moving average.
From a valuation standpoint, the stock is 96.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 53.0.
LogicBio Therapeutics, Inc's total revenue rose by inf% to $542K since the same quarter in the previous year.
Its net income has increased by 39.8% to $-7M since the same quarter in the previous year.
Finally, its free cash flow grew by 36.7% to $-8M since the same quarter in the previous year.
Based on the above factors, LogicBio Therapeutics, Inc gets an overall score of 4/5.